泰林生物(300813) - 2024 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2024 reached ¥86,185,149.14, representing a 42.15% increase compared to the same period last year[3] - Net profit attributable to shareholders was ¥4,732,621.73, a significant increase of 351.46% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥4,620,107.19, up 237.63% from the previous year[3] - The basic earnings per share for the quarter was ¥0.04, reflecting a 500.00% increase compared to the same period last year[3] - The total operating revenue for the third quarter of 2024 reached ¥242,467,278.88, an increase of 19.3% compared to ¥203,117,602.42 in the same period last year[15] - The total operating costs for the same period were ¥236,221,850.45, up from ¥193,303,198.02, reflecting a year-over-year increase of 22.2%[15] - The net profit for Q3 2024 was CNY 10,599,894.14, a decrease of 48.9% compared to CNY 20,765,694.34 in Q3 2023[16] - Operating profit for the quarter was CNY 12,850,755.64, down 43.5% from CNY 22,693,621.90 in the same period last year[16] - The total comprehensive income attributable to the parent company was CNY 11,314,672.20, down from CNY 21,311,951.81, a decrease of 46.9%[17] Assets and Liabilities - Total assets at the end of the reporting period were ¥962,089,074.17, a decrease of 1.17% from the end of the previous year[4] - The total assets as of September 30, 2024, were ¥962,089,074.17, down from ¥973,507,907.87 at the beginning of the period, a decrease of 1.6%[14] - The total liabilities decreased to ¥306,484,433.68 from ¥323,268,730.54, a reduction of 5.2%[15] - The equity attributable to shareholders of the parent company increased to ¥654,843,177.53 from ¥648,762,936.31, an increase of 0.2%[15] Cash Flow - The company's cash flow from operating activities showed a net outflow of ¥20,714,994.54, down 65.58% year-on-year[3] - The cash flow from investment activities saw a significant increase of 369.16% to ¥569,235,804.24, attributed to the continued purchase of financial products after their maturity[8] - The net cash flow from operating activities for Q3 2024 was -20,714,994.54 CNY, compared to -12,510,682.38 CNY in Q3 2023, indicating a decline in operational cash flow[19] - Total cash inflow from investment activities was 569,235,804.24 CNY, significantly higher than 121,351,287.20 CNY in the same period last year[19] - The net cash flow from investment activities was 28,422,441.32 CNY, recovering from a negative cash flow of -22,360,540.85 CNY in Q3 2023[19] - Cash inflow from financing activities totaled 15,645,426.70 CNY, down from 76,588,926.92 CNY in Q3 2023[19] - The net cash flow from financing activities was 4,725,027.41 CNY, compared to 18,243,451.57 CNY in the previous year[19] Shareholder Information - The number of common shareholders at the end of the reporting period was 11,207, with the largest shareholder holding 52.98%[10] - The number of restricted shares held by major shareholders increased to 51,455,196 shares, with specific release dates set for 2024 and 2025[12] Expenses - Operating costs rose by 35.23% to ¥126,295,460.96, attributed to increases in raw materials, labor costs, and manufacturing expenses[8] - Financial expenses surged by 144.47% to ¥3,361,208.48, mainly due to increased interest expenses on convertible bonds[8] - Research and development expenses increased to CNY 49,454,422.64, up from CNY 48,129,064.41, reflecting a growth of 2.7% year-over-year[16] - The tax expenses for the quarter were CNY 1,995,378.01, slightly down from CNY 2,112,940.61 in Q3 2023[16] - Other income decreased to CNY 7,231,506.67 from CNY 13,035,063.95, a decline of 44.5%[16] Government Support - The company received government subsidies amounting to ¥109,348.20 during the quarter, contributing positively to its financial performance[5]